Bioline RX News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.11.24	Earnings Preview For BioLine Rx (Benzinga)
25.03.24	Earnings Preview For BioLine Rx (Benzinga)
27.05.20	BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine (PR Newswire)
05.11.19	BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Mic... (PR Newswire)
31.10.19	BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019 (PR Newswire)
29.10.19	BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019 (PR Newswire)
03.09.19	BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors (PR Newswire)
07.05.19	BioLineRx to Report First Quarter 2019 Results on May 14, 2019 (PR Newswire)
07.05.19	BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors (PR Newswire)
28.03.19	BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update (PR Newswire)
04.02.19	BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer (PR Newswire)
02.01.19	BioLineRx to Present at the 2019 Biotech Showcase (PR Newswire)
06.12.18	BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York (PR Newswire)
08.11.18	BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update (PR Newswire)
01.11.18	BioLineRx to Report Third Quarter 2018 Results on November 8, 2018 (PR Newswire)
20.10.18	BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress (PR Newswire)
19.10.18	BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress (PR Newswire)
03.10.18	BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications (PR Newswire)
30.08.18	BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York (PR Newswire)
07.08.18	BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization (PR Newswire)
01.08.18	BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors (PR Newswire)
30.07.18	BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer (PR Newswire)
18.06.18	BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients (PR Newswire)
17.05.18	BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation (PR Newswire)
06.03.18	BioLineRx Reports Year End 2017 Financial Results (PR Newswire)
07.09.17	BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York (PR Newswire)
02.08.17	BioLineRx to Report Second Quarter 2017 Results on August 8, 2017 (PR Newswire)
26.07.17	BioLineRx Announces Additional Investment From BVF Partners L.P. (PR Newswire)
10.07.17	BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration (PR Newswire)
01.06.17	BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors (PR Newswire)
22.05.17	BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML (PR Newswire)
16.05.17	BioLineRx to Report First Quarter 2017 Results on May 25, 2017 (PR Newswire)
03.05.17	BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA (PR Newswire)
05.04.17	BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares (PR Newswire)
31.03.17	BioLineRx Prices $25 Million Underwritten Public Offering (PR Newswire)
30.03.17	BioLineRx Announces Underwritten Public Offering of its American Depositary Shares (PR Newswire)
27.03.17	BioLineRx's AGI-134 to be Presented at AACR 2017 (PR Newswire)
23.03.17	BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline (PR Newswire)
16.03.17	BioLineRx to Report Annual 2016 Results on March 23, 2017 (PR Newswire)
07.02.17	BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14 (PR Newswire)
17.01.17	BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (PR Newswire)
04.01.17	BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco (PR Newswire)
05.12.16	BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016 (PR Newswire)
21.11.16	BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.54	1.71 %	K V
CieFinRichemont	121.80	0.54 %	K V
Lonza Grp	529.20	0.49 %	K V
Givaudan	3’909.00	0.21 %	K V
Kuehne+Nagel Int	209.20	0.19 %	K V
ABB	49.60	-0.72 %	K V
Sika	229.40	-0.78 %	K V
Roche Hldg G	251.50	-0.79 %	K V
Swisscom	504.00	-0.98 %	K V
UBS Group	28.00	-1.23 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bioline RX Ltd.

Aktien Top/Flop

Meistgelesene Nachrichten